Long-term CXCR3 antagonist AMG487 mitigated acute graft-versus-host disease by inhibiting T cell activation in a murine model
Transplant Immunology · 2024
DOI: 10.1016/j.trim.2024.102128 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transplant Immunology, 2024. Verfasst von Miao Shengchao und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, China.…. Hauptthemen laut MEDLINE: Graft vs Host Disease, Receptors, CXCR3, Disease Models, Animal, Lymphocyte Activation. Die Arbeit nennt 39 Literaturangaben. Gefördert von: Shandong Qianfoshan Hospital.
Abstract (Originalsprache)
BACKGROUND: Lymphocyte migration plays a key role in the development of acute graft-versus-host disease (aGVHD). Blocking lymphocyte migration by targeting chemokine receptors, such as CXCR3, may be a promising strategy for preventing and treating aGVHD. Our previous studies have shown that short-term CXCR3 antagonist treatment combined with cyclosporine A alleviated aGVHD. However, the effect of long-term AMG487 treatment on aGVHD survival has not been thoroughly investigated. METHODS: A murine aGVHD model was used to examine the expression of CXCR3 in donor T cells. The effects of short- and long-term AMG487 treatment on aGVHD survival were assessed. The infiltration of donor T cells into the liver and spleen tissues and the activation of donor T cells in splenic tissues were also examined. RESULTS: CXCR3 was consistently highly expressed in donor T cells in a murine aGVHD model. Long-term AMG487 treatment, but not short-term, improved survival and aGVHD outcomes (p < 0.05). Furthermore, long-term AMG487 administration reduced the number of donor T cells in the liver but increased the number of donor T cells in the spleen (p < 0.05). Long-term AMG487 treatment also inhibited donor T cell activation in the spleen (p < 0.05). CONCLUSION: This study demonstrates that long-term AMG487 treatment has a potential therapeutic effect on aGVHD and could be used as a novel therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, China. Electronic address: 2004piaopiao@163.com.
- Department of Hematology, Peking University First Hospital, Beijing, China.
Förderung
- Shandong Qianfoshan Hospital
Zitieren
APA
Shengchao, M., Bo, T., Huihui, L., Chenchen, Q., Beichen, L., Zhenhua, W., Ning, M., & Yongjin, S. (2024). Long-term CXCR3 antagonist AMG487 mitigated acute graft-versus-host disease by inhibiting T cell activation in a murine model. Transplant Immunology. https://doi.org/10.1016/j.trim.2024.102128
Vancouver
Shengchao M, Bo T, Huihui L, Chenchen Q, Beichen L, Zhenhua W, et al. Long-term CXCR3 antagonist AMG487 mitigated acute graft-versus-host disease by inhibiting T cell activation in a murine model. Transplant Immunology. 2024. doi:10.1016/j.trim.2024.102128
BibTeX
@article{Shengchao2024,
author = {Shengchao, Miao and Bo, Tang and Huihui, Liu and Chenchen, Qin and Beichen, Liu and Zhenhua, Wang and Ning, Ma and Yongjin, Shi},
title = {Long-term CXCR3 antagonist AMG487 mitigated acute graft-versus-host disease by inhibiting T cell activation in a murine model},
journal = {Transplant Immunology},
year = {2024},
doi = {10.1016/j.trim.2024.102128}
}
EUVIMED